DYSLIPIDEMIA IN CHRONIC KIDNEY DISEASE

被引:0
|
作者
Singh, Manish Kumar [1 ]
Charan, V. D. [1 ]
Parasher, Ishan [2 ]
Pankaj, Pranjal [1 ]
Kumar, Shrawan [1 ]
Gupta, Kusum [1 ]
Singh, Vindhyawasini Prasad [1 ]
机构
[1] Rama Med Coll Hosp & Res Ctr, Dept Med, Kanpur, Uttar Pradesh, India
[2] Rama Med Coll Hosp & Res Ctr, Dept Biochem, Kanpur, Uttar Pradesh, India
关键词
Chronic kidney disease; dyslipidemia; Cholesterol; LDL; HDL; VLDL;
D O I
10.14260/jemds/1224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Chronic kidney disease encompasses a spectrum of different pathophysiological processes associated with abnormal kidney function and a progressive decline in glomerular filtration rate (GFR). Chronic kidney disease is a universal medical problem across the globe. Unless treated, it may lead to grave consequences. Chronic kidney disease leads to impairment of excretory, metabolic and endocrine functions of the kidney. As other complications of CKD occur, likewise it also results in profound lipid disorders In view of the effect of dyslipidemia on cardiovascular risk and possibly on the progression of renal disease, treatment seems sensible, although evidence is not abundant. AIMS AND OBJECTIVES: 1. Study the lipid profile in the cases of chronic kidney disease. 2. Study the significance of dyslipidemia in chronic kidney disease. MATERIAL AND METHODS: The study was carried out in a group of patients who were admitted and patients visiting the outpatient department of the Department of Medicine at Rama Medical College, Kanpur, Patients were selected by adhering strictly to certain inclusion (Patients of chronic kidney disease on conservative treatment and on haemodialysis or peritoneal dialysis) and exclusion criteria (renal failure other than CKD or on hypolipidemic drugs). RESULTS: In our study 30% of the cases, the cholesterol value is within normal limits. 18% cases its level is high i. e. above 240 and in rest 52 % of cases it is within the borderline high range. The mean triglyceride is 218.74 mg/dl in patients of CKD and is 87.04 mg/dl in control subjects which is statistically very significant. The mean VLDL is 43.78 mg/dl in patients of CKD and is 17.41 mg/dl in control subjects which is statistically very significant. 90% cases had HDL < 40 mg/dl. 6% of the patients had serum LDL value within normal range. 32% of the patients had optimal serum LDL cholesterol value near or above normal range. 36 % of the patient had serum LDL value in borderline high range. 12% of the patient had serum LDL cholesterol value in high range. 14% of the patient had serum LDL cholesterol value in very high range. The mean LDL/HDL ratio is 4.44 in patients of CKD and is 2.66 in control subjects. The mean TG/HDL ratio is 7.02 in patients of CKD and is 1.88 in control subjects. Mean TG/LDL ratio is 1.66 in patients of CKD and is 0.71 in control subjects. CONCLUSION: In the cases of chronic kidney disease there is dyslipidemia with maximum impact on level of triglycerides with a very significant increase. The level of total cholesterol is increased, that of HDL is decreased and level of VLDL is increased. These changes are occurring independently in chronic kidney disease.
引用
收藏
页码:6864 / 6875
页数:12
相关论文
共 50 条
  • [21] Role of Dyslipidemia in Patients With Chronic Kidney Disease
    Marino, Anna
    Tannock, Lisa R.
    POSTGRADUATE MEDICINE, 2013, 125 (04) : 28 - 37
  • [22] Statins for treatment of dyslipidemia in chronic kidney disease
    Shurraw, Sabin
    Tonelli, Marcello
    PERITONEAL DIALYSIS INTERNATIONAL, 2006, 26 (05): : 523 - 539
  • [23] Dietary Lipids and Dyslipidemia in Chronic Kidney Disease
    Kochan, Zdzislaw
    Szupryczynska, Natalia
    Malgorzewicz, Sylwia
    Karbowska, Joanna
    NUTRIENTS, 2021, 13 (09)
  • [24] Dyslipidemia promotes the progression of chronic kidney disease
    Liu Zhang-suo
    Liu Dong-wei
    CHINESE MEDICAL JOURNAL, 2013, 126 (07) : 1203 - 1206
  • [25] Dyslipidemia, chronic kidney disease, atherosclerotic cardiovascular disease, and statins
    Kawada, Tomoyuki
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (03) : 569 - 570
  • [26] Dyslipidemia, chronic kidney disease, atherosclerotic cardiovascular disease, and statins
    Tomoyuki Kawada
    Cardiovascular Drugs and Therapy, 2022, 36 : 569 - 570
  • [27] Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
    Suh, Sang Heon
    Kim, Soo Wan
    DIABETES & METABOLISM JOURNAL, 2023, 47 (05) : 612 - 629
  • [28] Statins in the management of dyslipidemia associated with chronic kidney disease
    Murray Epstein
    Nosratola D. Vaziri
    Nature Reviews Nephrology, 2012, 8 : 214 - 223
  • [29] Thyroid dysfunction and dyslipidemia in chronic kidney disease patients
    Khatiwada, Saroj
    Rajendra, K. C.
    Gautam, Sharad
    Lamsal, Madhab
    Baral, Nirmal
    BMC ENDOCRINE DISORDERS, 2015, 15
  • [30] Statins in the management of dyslipidemia associated with chronic kidney disease
    Epstein, Murray
    Vaziri, Nosratola D.
    NATURE REVIEWS NEPHROLOGY, 2012, 8 (04) : 214 - 223